Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/9587
Title: | Integrase strand transfer inhibitors (INSTIS) resistance mutations in HIV-1 infected Turkish patients | Authors: | Sayan, M. Gündüz, A. Ersöz, G. İnan, A. Deveci, A. Özgür, G. Sargın, F. |
Keywords: | DNA sequencing Dolutegravir Drug resistance Elvitegravir HIV-1 integrase Integrase inhibitors Raltegravir anti human immunodeficiency virus agent elvitegravir integrase integrase strand transfer inhibitor proteinase raltegravir RNA directed DNA polymerase unclassified drug virus RNA codon integrase inhibitor adult Article CD4+ T lymphocyte cytomegalovirus infection delta agent hepatitis female hepatitis B hepatitis C human Human immunodeficiency virus 1 Human immunodeficiency virus 1 infection Human immunodeficiency virus infected patient lung tuberculosis major clinical study male mixed infection priority journal Pseudomonas pneumonia structural gene thrush toxoplasmosis Turkish citizen virus detection virus mutation aged amino acid substitution antiviral resistance CD4 lymphocyte count drug effects genetics genotype HIV Infections microbial sensitivity test middle aged mutation risk factor transmission Turkey virology virus load young adult Adult Aged Amino Acid Substitution CD4 Lymphocyte Count Codon Coinfection Drug Resistance, Viral Female Genotype HIV Integrase Inhibitors HIV-1 Humans Male Microbial Sensitivity Tests Middle Aged Mutation Risk Factors RNA, Viral Viral Load Young Adult |
Publisher: | Taylor and Francis Ltd. | Abstract: | Objectives: Integrase strand transfer inhibitor (INSTI) is a new class of antiretroviral (ARV) drugs designed to block the action of the integrase viral enzyme, which is responsible for insertation of the HIV-1 genome into the host DNA. The aim of this study was to evaluate for the first time INSTI resistance mutations in Turkish patients. Methods: This study was conducted in Turkey, between April 2013 and April 2015 using 169 HIV-1-infected patients (78 ARV naive patients and 91 ARV-experienced patients). Laboratory and clinical characteristics of ARV naive and ARV-experienced patients were as follows: gender (M/F): 71/7 and 80/11, median age: 38 and 38.4; median CD4+ T-cell: 236 and 216 cells/mm3, median HIV-1 RNA: 4.95+E5 and 1.08E+6 copies/ml. Population-based seqeunces of the reverse transcriptase, protease, and integrase domains of the HIV-1 pol gene were used to detect HIV-1 drug resistance mutations. Result: INSTI resistance mutations were not found in recently diagnosed HIV-1-infected patients. However, ARV-experienced patients had major resistance mutations associated with raltegravir and elvitegravir; the following results were generated:F121Y, Y143R, Q148R and E157Q (6/91 – 6.6%). Conclusions: The prevalence of INSTI resistant mutations in ART-experienced patients suggested that resistance testing must be incorporated as an integral part of HIV management with INSTI therapies. © 2016 Informa UK Limited, trading as Taylor & Francis Group. | URI: | https://hdl.handle.net/11499/9587 https://doi.org/10.1080/15284336.2016.1153303 |
ISSN: | 1528-4336 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
SCOPUSTM
Citations
7
checked on Nov 30, 2024
WEB OF SCIENCETM
Citations
10
checked on Dec 4, 2024
Page view(s)
28
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.